Warning. Research only: not approved by the FDA for any use in people. Information is for scientific awareness only. Not a recommendation to use, buy or compound.
No perspectives yet — be the first!
Be the first verified clinician to share how you read the research on CJC-1295.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
CJC-1295 is a maleimido derivative of hGRF(1-29); structure in first source.
CJC-1295
Not approved for use in people. Mostly lab or animal research.
We have not yet attached proof for an evidence level.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
We have not yet attached proof for an evidence level.
Not FDA-approved. Nominations withdrawn from FDA's 503A category 2 (significant safety risk) list in 2026. Not on the 503A bulks list.
Last verified: Nov 11, 2026
Scientific views only. No use in patients or dosing is discussed.
Share your scientific view of the published evidence on CJC-1295.
Your view of the published research guides colleagues
Your name is never shown, only your specialty and region
About the published research. No use in patients or dosing
